stockrow
Saturday 7 November 2026
Export VYGR’s income statement to Excel — free account
Voyager Therapeutics, Inc.
VYGR Healthcare Biotechnology
Voyager Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.4 million, down 49.5% from fiscal 2024.
- Revenue
- −70.0%
- EPS
- +14.9%
- Free cash flow
- +37.1%
Quarter to September 2026, against a year earlier
1.90
0.18
+10.47%
Follow VYGR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(48.29%) | (52.26%) | (54.09%) | (58.90%) | |
Piotroski F-Score |
2 | 2 | 3 | 3 | |
| (37.10%) | (40.74%) | (41.45%) | (44.92%) | ||
ROIC |
0.00% | (247.40%) | (192.55%) | (249.55%) | |
Return on Tangible Assets |
(63.25%) | (82.29%) | (89.97%) | (97.34%) | |
Average Days of Receivables |
17.29 | 16.45 | 33.41 | 62.13 | |
Free Cash Flow per Share |
(2.30) | (2.18) | (2.01) | (1.77) | |
Free Cash Flow |
(135.06) | (129.94) | (121.42) | (109.19) | |
Capital Expenditures |
(2.60) | (1.95) | (0.85) | — | |
| Other line items | |||||
Cash ROIC |
(34.41%) | (41.23%) | (44.85%) | (45.14%) | |
Accounts Receivable Turnover |
19.73 | 19.44 | 12.14 | 6.04 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
333.57% | 350.06% | 343.77% | 426.02% | |
Selling, General and Administrative Expense of Revenue |
92.99% | 99.10% | 96.31% | 124.10% | |
Share Based Compensation of Revenue |
36.63% | 37.27% | 34.54% | 43.99% | |
Operating CF/Net income |
1.11 | 1.10 | 1.12 | 1.04 | |
Depreciation/Fixed assets |
0.08 | 0.13 | 0.18 | 0.25 | |
Capex/Depreciation |
(2.39) | (1.19) | (0.42) | 0.00 | |
Revenue per Share |
0.69 | 0.61 | 0.57 | 0.41 | |
Operating CF per Share |
(2.26) | (2.15) | (1.99) | (1.77) | |
Capex per Share |
(0.04) | (0.03) | (0.01) | 0.00 | |
Capex to Sales |
0.06 | 0.05 | 0.02 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026